Our meta-analysis revealed that VEGF overexpression was significantly associated with poorer prognosis of NHL (HR = 1.66, 95% CI: 1.25–2.22, P = 0.000), but not with clinicopathological features of NHL, such as performance status (OR = 0.843, 95% CI: 0.39–1.882, P = 0.640), LDH level (OR = 0.981, 95% CI: 0.636–1.51, P = 0.930), IPI score (OR = 0.452, 95% CI: 0.147–1.389, P = 0.170), tumor staging (OR = 0.756, 95% CI: 0.363–1.574, P = 0.450), B symptoms (OR = 0.961, 95% CI: 0.649–1.422, P = 0.840), or relapse (OR = 0.736, 95% CI: 0.362–1.5, P = 0.400). This evidence concerns the gene VEGFA and non-Hodgkin lymphoma.